Enlivex Ltd. Ordinary Shares (ENLV)

• Market cap: $256M
• 1 day: -0.92%
• 5 days: 2.86%
• 1 month: 2.86%
• 3 months: 29.36%
• 6 months: 2.86%
• Year to date: 43.07%
• 1 year: -3.57%
• 5 years: -92.02%
• 10 years: -99.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Employees: 36